Improved fermentation and isolation procedures for antitumor antimetabolites U-42,126 and U-43,795 increased drug yields 30-fold. The sensitivity limit of a newly developed assay is 0.03 sg of U-42,126 and 2.0,ug of U-43,795 per ml. The in vitro antimicrobial effect of both drugs was antagonized by histidine.
Antitumor antibiotic U-42,126 (NSC-163501) was discovered by utilizing an in vitro screen designed for detection of antimetabolites (2) . Its production by Streptomyces sviceus (3), isolation and structure determination as a S,5S-aamino -3 chloro -4,5 -dihydro -5 -isoxazoleacetic acid (7) , and biological activity (5) were described in a series of communications in 1972 and 1973 . The antibiotic has the unique structure shown in Fig. 1 . Recently a related amino acid, U-43,795 (NSC-176324) ( Fig. 1) , was isolated from the same fermentation producing U-42,126 and found to have hydroxylated structure a S,4S,5R-a-amino-3-chloro-4-hydroxy-4,5-dihydro-5-isoxazoleacetic acid (6) . The presence of U-43,795 in mixtures with U-42,126 was originally obscured by the low antibacterial activity (8) of U-43,795 towards the organism used to monitor production and isolation. However, in spite of diminished antibacterial activity, the new amino acid had significant antitumor activity against L1210 lymphoid leukemia in mice (8) .
The interesting antitumor activity of both U-42,126 and U-43,795 against murine leukemia L1210 necessitated the preparation of substantial amounts of each for evaluation in other tumor systems. Since previous technology (3, 7) was inadequate for this task, a considerable effort was spent to improve the microbiological production, to devise simplified and more efficient methods of extraction and separation of the agents, and to develop a highly sensitive microbiological assay.
We also investigated which of the naturally occurring metabolites can reverse (prevent) the inhibition of a sensitive microorganism by pure U-42,126. The results of all these studies are presented in this communication.
MATERIALS AND METHODS
Production in 5,000-liter fermentation tanks. (i) Primary vegetative inoculum. Primary vegetative inoculum of S. sviceus was produced in medium containing (per liter of distilled water): glucose, 10 g; peptone (Difco), 10 g; and yeast extract, 2.5 g. It was inoculated with vegetative inoculum stored in a liquid N2 storage tank. The cultivation was done in 500-ml nonstippled flasks (with 100 ml of medium) on a rotary shaker (270 rpm) that were incubated for 72 h at 28 C.
(ii) Secondary vegetative inoculum. Primary vegetative inoculum (300 ml) was used to inoculate a 250-liter seed vessel containing (per liter) the following medium: cerelose, 10 g; steepwater, 10 g (Corn Products Co., Englewood Cliffs, N.J.); Pharmamedia, 2 
These columns were repeated for each of the four 4,000-liter fermentations and for the partially loaded trail columns of Dowex 50 x 16. In addition, a pool of material for a salvage run was collected from IR 45 forerun and trail fractions, impure silica gel fractions, and crystallization mother liquors. This material was recycled to the IR 45 column and processed as described above.
Microbiological assay. A substantially more sensitive microbiological assay over that previously reported (5) was developed. The assay medium was the previously described (2) completely synthetic agar. It was inoculated with spores of Bacillus subtilis UC-902
(1 ml/liter; viable count 7 x 1011 cells/ml) and the assay plates were prepared in the conventional way. The crystalline U-42,126 was diluted in water to reach concentrations suitable for standard curve: 0.1, 0.077, 0.059, 0.045, and 0.035 Atg/ml. Such Reversal (antagonism) studies. During the early studies done with whole fermentation liquors or partially purified preparations it was possible to prevent the inhibition by U-42,126 of the susceptible microorganism by incorporating histidine into the cultivation media. When preparations of the drugs became available, a more detailed study was conducted. Assay plates inoculated with B. subtilis UC-902 were prepared as described above. For some plates the synthetic agar was further supplemented with different concentrations of several potential reversing (antagonizing) agents. The drug was applied at six increasing concentrations on 1/2-inch paper disks. Then the assay plates were incubated for 18 h at AMINO ACID ANTITUMOR ANTIMETABOLITES 40 C, and the resulting zones of inhibition were recorded. An identical experiment was carried out to study the reversal pattern of U-43,795.
RESULTS AND DISCUSSION Fermentations and isolation. Table 1 presents the results of a typical fermentation run in 500-ml flasks done under the original fermentation conditions (3) and one carried out with the improved methods.
It was our experience that by using the new fermentation conditions the titers of the drug were increased 30-to 40-fold.
The titers of U-42,126 reached after 92 h of incubation in 5,000-liter tanks were (Ag/ml):
tank number 1, 33; tank 2, 43; tank 3, 49; and tank 4, 35.
The titers of U-43,795 could not be estimated by B. subtilis assay since its activity was less than 0.1% that of U-42,126; however, the drugs were apparently produced in roughly equivalent amounts based on isolated yields.
Successive processing of 16,000 liters of clarified fermentation broth with Dowex 50 (H form) and then Amberlite IR 45 (OH form) afforded a mixture of the two agents. A relatively efficient resolution on silica gel afforded readily crystallized fractions of each component yielding, after recrystallization, 169 g of pure U-42,126 and 167 g of pure U-43,795.
Microbiological assay. A typical doseresponse line of U-42,126 on B. subtilis UC-902 is presented in Fig. 2 . The assay can detect concentrations of 0.03 jig of U-42,126 per ml.
The lowest detectable concentration of U-43,795 was 2.0,g/ml. The slope of dose-response curve was about 6 mm for a twofold concentration increase, and the angle of the slope was comparable to that of U-42,126.
Incubation of the assay plates at 39 to 40 C is superior to the commonly used 37 C. The sensitivity of the assay can be further increased by -70% by cooling the spotted assay plates for 2 to 3 h at 4 C prior to the incubation.
Reversal (antagonism) studies. The in vitro antimicrobial effect of U-42,126 was antagonized quite strongly by histidine (Table 2 ). In other experiments we established that of all the common purines and pyrimidines tested, only deoxyinosine demonstrates slight antagonism. None of the vitamins or any other amino acids (except histidine) prevented the in vitro effect of U-42,126. The antagonism by histidine was rather unusual, though. It was demonstrable at concentration as low as 0.015 ,ug/ml and kept increasing until the level of 1.0 gg/ml was reached. However, any further increase in its concentrations had no additional reversing effect. The zones of inhibition were about the same on plates containing 1.0, 12.5, or 100 ,Ag of histidine per ml as supplement in the cultivation media. This is a rather unusual situation and is in complete disagreement with our past experience with such antimetabolites as psicofuranine (1) or 5-azaycytidine (3) . One of the possible explanations of this unusual observation could be the presence of small amounts of another material that is in vitro active against the test microorganism but that is not antagonized by histidine. However, elemental analysis (C, H, N, Cl, and equivalent weight), spectral analysis (infrared, ultraviolet, nuclear magnetic resonance, and circular dichroism), and chromatographic analysis (silica gel and paper) indicated that the sample utilized for histidine reversal studies was homogenous and consistent with the assigned structure. The reversal pattern of U-43,795 was comparable to that of U-42,126 (Table 3) .
